US stock futures flounder amid tech weakness, Fed caution
SOUTH SAN FRANCISCO - CERo Therapeutics Holdings, Inc. (NASDAQ:CERO) announced Wednesday that its board of directors has approved a one-for-twenty reverse stock split of the company’s common stock, effective June 13, 2025. The announcement comes as the stock trades near its 52-week low of $0.36, having declined over 95% in the past six months according to InvestingPro data.
The company’s common stock will begin trading on a split-adjusted basis on the Nasdaq Capital Market at market open on June 13, with a new CUSIP number of 71902K402.
The reverse split will reduce CERo’s outstanding common shares from approximately 10.3 million to about 516,092 shares. Stockholders who would otherwise receive fractional shares will automatically receive an additional fraction to round up to the next whole share.
Proportional adjustments will be made to stock options, equity incentive plans, preferred stock conversion terms, and outstanding warrants. Stockholders with shares in book-entry form or held through brokers will see changes reflected in their accounts after June 13.
The split ratio falls within the range previously authorized by CERo stockholders at the company’s annual meeting held on May 29, 2025.
CERo Therapeutics is developing engineered T cell therapeutics for cancer treatment. Its platform creates what the company calls Chimeric Engulfment Receptor T cells (CER-T), which use phagocytic mechanisms to destroy cancer cells.
The company plans to initiate clinical trials for its lead product candidate, CER-1236, in 2025 for hematological malignancies, according to the press release statement.
In other recent news, CERo Therapeutics Holdings, Inc. has made several key announcements that could impact investors. The company has initiated a Phase 1 clinical trial for its lead product candidate, CER-1236, targeting acute myeloid leukemia (AML). This trial marks the first human dosing of the novel CAR-T therapy candidate. CERo has also issued additional Series D Preferred Stock, raising $750,000, with the potential to raise up to $2.25 million more. The funds are intended to support clinical programs and the activation of new trial sites.
In addition, CERo has expanded its intellectual property portfolio by securing two U.S. patents and one European patent application related to its CER-1236 compound. These patents strengthen the company’s position in engineered T cell therapeutics. Meanwhile, Maxim Group has initiated coverage on CERo with a Buy rating and a $3 price target, citing the potential of the company’s innovative CER-T technology. The firm highlights CER-1236’s dual action mechanism, which could offer advantages over traditional CAR-T therapies.
Furthermore, CERo has regained compliance with Nasdaq’s minimum stockholders’ equity requirement, following financial maneuvers including a private placement of Series D Preferred Stock. CEO Chris Ehrlich expressed gratitude for investor support and emphasized the company’s focus on advancing its clinical programs. With these developments, CERo Therapeutics continues to progress in its mission to revolutionize cancer treatment through its proprietary technology.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.